Výsledky vyhledávání - "Stanford Jhee"

A Randomized, Double-Blind, Placebo- and Active-Controlled, Escalating Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Profiles of Subcutaneous Eflapegrastim in Healthy Japanese and Caucasian Subjects

Autor: Yoomin Jeon, Nora Lee, Seungjae Baek, JaeDuk Choi, Stanford Jhee, Howard Lee

Publikováno v: Drugs in RD. 22(1)

Eflapegrastim (RolontisThis phase I study aimed to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and immunogenicity of eflapegrastim following a single subcutaneous administration to healthy Japanese and Caucasian sub

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f620ca0c1c52096d248491c8d2c2e0b0
https://pubmed.ncbi.nlm.nih.gov/34993933

Zobrazit plný text záznamu

A first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of KM-819 (FAS-associated factor 1 inhibitor), a drug for Parkinson's disease, in healthy volunteers

Autor: Wonsuk, Shin, Kyoung Soo, Lim, Min-Kyoung, Kim, Hyun Sook, Kim, Jihwa, Hong, Stanford, Jhee, Joseph, Kim, Sungeun, Yoo, Yeon-Tae, Chung, Jae Moon, Lee, Doo-Yeoun, Cho

Publikováno v: Drug Design, Development and Therapy

Background KM-819 is a novel FAS-associated factor 1 (FAF1) inhibitor, and a neuroprotective agent, under clinical development for the treatment of Parkinson’s disease as a disease-modifying drug. Methods This first-in-human, single and multiple as

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::c01409b89783ace6db88ffb49f9bb9ea
https://pubmed.ncbi.nlm.nih.gov/30992659

Zobrazit plný text záznamu

Implementing a Memory Clinic Model to Facilitate Recruitment into Early Phase Clinical Trials for Mild Cognitive Impairment and Alzheimer's Disease

Autor: D. Gullaba, Svetlana Semenova, Zyanya Mendoza, Lovingly Park, Sophie Lee, C. Kouhanim, C. Aguilar, K. Patrick, Lev Gertsik, Stanford Jhee

Publikováno v: The journal of prevention of Alzheimer's disease. 6(2)

Background: The recruitment challenges for MCI and AD subjects into clinical trials are well known, and this is particularly true for early phase studies. Currently, only 10-20% of all patients who are referred for research from the community are tri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88f70054f29b70de99742464d64bf60e
https://pubmed.ncbi.nlm.nih.gov/30756120

Zobrazit plný text záznamu

The effect of LCZ696 (sacubitril/valsartan) on amyloid‐β concentrations in cerebrospinal fluid in healthy subjects

Autor: Marie-Anne Valentin, Thomas Langenickel, Chiaki Tsubouchi, Markus Hinder, Hakop Gevorkyan, Stanford Jhee, Surya Ayalasomayajula, Iris Rajman, Parasar Pal

Publikováno v: British Journal of Clinical Pharmacology

Aims LCZ696 (angiotensin receptor neprilysin inhibitor) is a novel drug developed for the treatment of heart failure with reduced ejection fraction. Neprilysin is one of multiple enzymes degrading amyloid‐β (Aβ). Its inhibition may increase Aβ l

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::250e09afae5fd87a1467ccfa17cfcd31
https://doi.org/10.1111/bcp.12861

Zobrazit plný text záznamu

Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects

Autor: Zhigang Yu, Andrew Shenker, Frank LaCreta, Stanford Jhee, Janice Pursley, Jessie Wang, Charles Frost, Alexander Bragat

Publikováno v: Clinical Pharmacology : Advances and Applications

Charles Frost,1 Andrew Shenker,1 Stanford Jhee,2 Zhigang Yu,1 Jessie Wang,3 Alexander Bragat,1 Janice Pursley,4 Frank LaCreta1 1Exploratory Clinical and Translational Research, Bristol-Myers Squibb, Princeton, NJ, USA; 2PAREXEL International Early Ph

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d901ffc0feca5087f7002b7bb56e87a7
https://www.dovepress.com/evaluation-of-the-single-dose-pharmacokinetics-and-pharmacodynamics-of-peer-reviewed-article-CPAA

Zobrazit plný text záznamu

Pharmacokinetic Profile of Orally Administered Scyllo-Inositol (Elnd005) in Plasma, Cerebrospinal Fluid and Brain, and Corresponding Effect on Amyloid-Beta in Healthy Subjects

Autor: Pamela Garzone, Victor Xu, Jesse M. Cedarbaum, Thao Tran, Susan Abushakra, Aleksandra Pastrak, Larry Ereshefsky, Stanford Jhee, Martin Koller, Brian D. Ross, Earvin Liang

Publikováno v: Clinical Pharmacology in Drug Development. 2:186-194

ELND005 (scyllo-inositol), an endogenous inositol stereoisomer, is being investigated as an oral treatment for Alzheimer's disease (AD). Pharmacokinetics of ELND005 in plasma, cerebrospinal fluid (CSF), and brain was characterized in healthy young su

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1bab624abd53c5b659189ad55a033ad3
https://doi.org/10.1002/cpdd.14

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání